Neighborhood deprivation and warfarin, aspirin and statin prescription A cohort study of men and women treated for atrial fibrillation in Swedish primary care

International Journal of Cardiology

Volumn 187, Issue 1, 2015, Pages 547-552

  Carlsson, Axel C ^a,b   Wändell, Per ^a   Gasevic, Danijela ^c   Sundquist, Jan ^d,e   Sundquist, Kristina ^d,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Cardiovascular epidemiology; CHADS2; Neighborhood; Pharmacotherapy; Socio economic status; Sweden; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MIDDLE AGED; NEIGHBORHOOD; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIAL ISOLATION; SOCIAL STATUS; SOCIAL WELFARE; SWEDISH CITIZEN; VERY ELDERLY; CLINICAL PRACTICE; DEMOGRAPHY; PRESCRIPTION; PRIMARY HEALTH CARE; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA; STROKE; SWEDEN;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; COHORT STUDIES; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; RESIDENCE CHARACTERISTICS; SOCIOECONOMIC FACTORS; STROKE; SWEDEN; WARFARIN;

EID: 84929193061     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.04.005     Document Type: Article

References (40)

1. A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, J.V. Selby, et al., Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study, JAMA 285 (2001) 2370-2375.
2. S. Stewart, C.L. Hart, D.J. Hole, J.J. McMurray, Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study, Heart 86 (2001) 516-521.
3. P.E.Wandell, A.C. Carlsson, J. Sundquist, S.E. Johansson,M. Bottai, K. Sundquist, Pharmacotherapy and mortality in atrial fibrillation-a cohort of men and women 75 years or older in Sweden, Age Ageing 44 (2) (2015) 232-238 PMID: 25324331.
4. C.T. January, L.S. Wann, J.S. Alpert, H. Calkins, J.E. Cigarroa, J.C. Cleveland Jr., et al., 2014 AHA/ACC/HRS guideline for themanagement of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society, Circulation 130 (2014) 2071-2104.
5. P.A. Wolf, R.D. Abbott, W.B. Kannel, Atrial fibrillation as an independent risk factor for stroke: The Framingham study, Stroke 22 (1991) 983-988.
6. T. Kitago, R.S. Marshall, Strategies for early stroke recovery: What lies ahead? Curr. Treat. Options Cardiovasc. Med. 17 (2015) 356.
7. B.F. Gage, A.D.Waterman, W. Shannon,M. Boechler,M.W. Rich, M.J. Radford, Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation, JAMA 285 (2001) 2864-2870.
8. M.C. Fang, A.S. Go, Y. Chang, L. Borowsky, N.K. Pomernacki, D.E. Singer, Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation, J. Am. Coll. Cardiol. 51 (2008) 810-815.
9. A.S. Go, E.M. Hylek, L.H. Borowsky, K.A. Phillips, J.V. Selby, D.E. Singer, Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study, Ann. Intern. Med. 131 (1999) 927-934.
10. A.S. Go, E.M. Hylek, K.A. Phillips, L.H. Borowsky, L.E. Henault, Y. Chang, et al., Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study, Circulation 102 (2000) 11-13.
11. D.E. Singer, Y. Chang, M.C. Fang, L.H. Borowsky, N.K. Pomernacki, N. Udaltsova, et al., The net clinical benefit of warfarin anticoagulation in atrial fibrillation, Ann. Intern. Med. 151 (2009) 297-305.
12. J.T. Zhang, K.P. Chen, S. Zhang, Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: A meta-analysis, Medicine (Baltimore) 94 (2015) e409.
13. A.C. Carlsson, P. Wandell, K. Sundquist, S.E. Johansson, J. Sundquist, Effects of prescribed antihypertensives and other cardiovascular drugs on mortality in patients with atrial fibrillation and hypertension: A cohort study from Sweden, Hypertens. Res. 37 (2014) 553-559.
14. P.Wandell, A.C. Carlsson, J. Sundquist, S.E. Johansson, M. Bottai, K. Sundquist, Effects of prescribed antithrombotics and other cardiovascular pharmacotherapies on allcause mortality in patients with diabetes and atrial fibrillation - a cohort study from Sweden using propensity score analyses, Diabetol. Metab. Syndr. 6 (2014) 2.
15. P. Wandell, A.C. Carlsson, K. Sundquist, S.E. Johansson, J. Sundquist, Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: A cohort study, Eur. J. Clin. Pharmacol. 69 (2013) 279-287.
16. A.C. Carlsson, P. Wandell, K. Sundquist, S.E. Johansson, J. Sundquist, Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: A Swedish study of prescribed drugs in primary care in 2002 and 2007, Eur. J. Clin. Pharmacol. 69 (2013) 245-253.
17. N.L. Glazer, S. Dublin, N.L. Smith, B. French, L.A. Jackson, J.B. Hrachovec, et al., Newly detected atrial fibrillation and compliance with antithrombotic guidelines, Arch. Intern. Med. 167 (2007) 246-252.
18. N.K. Choudhry, S.B. Soumerai, S.L. Normand, D. Ross-Degnan, A. Laupacis, G.M. Anderson,Warfarin prescribing in atrial fibrillation: The impact of physician, patient, and hospital characteristics, Am. J. Med. 119 (2006) 607-615.
19. J.M. Bachmann, M. Majmudar, C. Tompkins, R.S. Blumenthal, J.E. Marine, Lipidaltering therapy and atrial fibrillation, Cardiol. Rev. 16 (2008) 197-204.
20. A.V. Diez Roux, Investigating neighborhood and area effects on health, Am. J. Public Health 91 (2001) 1783-1789.
21. A.V. Diez Roux, S.S. Merkin, D. Arnett, L. Chambless, M. Massing, F.J. Nieto, et al., Neighborhood of residence and incidence of coronary heart disease, N. Engl. J. Med. 345 (2001) 99-106.
22. B. Zoller, X. Li, J. Sundquist, K. Sundquist, Neighbourhood deprivation and hospitalization for atrial fibrillation in Sweden, Europace 15 (2013) 1119-1127.
23. K. Hemminki, X. Li, K. Sundquist, Familial risks for nerve, nerve root and plexus disorders in siblings based on hospitalisations in Sweden, J. Epidemiol. Community Health 61 (2007) 80-84.
24. X. Li, J. Sundquist, K. Sundquist, Socioeconomic and occupational risk factors for rheumatoid arthritis: A nationwide study based on hospitalizations in Sweden, J. Rheumatol. 35 (2008) 986-991.
25. K. Sundquist, X. Li, Coronary heart disease risks in first-and second-generation immigrants in Sweden: A follow-up study, J. Intern. Med. 259 (2006) 418-427.
26. P.E.Wandell, A.C. Carlsson, K. Sundquist, S.E. Johansson, J. Sundquist, Totalmortality among levothyroxine-treated women with atrial fibrillation in Swedish primary health care, Int. J. Cardiol. 152 (2011) 147-148.
27. K.M. Henriksson, B. Farahmand, S. Johansson, S. Asberg, A. Terent, N. Edvardsson, Survival after stroke-the impact of CHADS2 score and atrial fibrillation, Int. J. Cardiol. 141 (2010) 18-23.
28. M.K. Kapral, H. Wang, M. Mamdani, J.V. Tu, Effect of socioeconomic status on treatment and mortality after stroke, Stroke 33 (2002) 268-273.
29. M. Joynt, M.K. Train, B.W. Robbins, J.S. Halterman, E. Caiola, R.J. Fortuna, The impact of neighborhood socioeconomic status and race on the prescribing of opioids in emergency departments throughout the United States, J. Gen. Intern. Med. 28 (2013) 1604-1610.
30. J.P. Kitzmiller, R.E. Foraker, K.M. Rose, Lipid-lowering pharmacotherapy and socioeconomic status: Atherosclerosis Risk In Communities (ARIC) surveillance study, BMC Public Health 13 (2013) 488.
31. A.C. Carlsson, B. Starrin, B. Gigante, K. Leander, M.L. Hellenius, U. de Faire, Financial stress in late adulthood and diverse risks of incident cardiovascular disease and allcause mortality in women and men, BMC Public Health 14 (2014) 17.
32. A.C. Carlsson, P.E.Wandell, G. Journath, U. de Faire, M.L. Hellenius, Factors associated with uncontrolled hypertension and cardiovascular risk in hypertensive 60-year-old men and women-a population-based study, Hypertens. Res. 32 (2009) 780-785.
33. E. Pimenta, M. Stowasser, Uncontrolled hypertension: Beyond pharmacological treatment, Hypertens. Res. 32 (2009) 729-731.
34. P. Amstislavski, A. Matthews, S. Sheffield, A.R. Maroko, J.Weedon, Medication deserts: Survey of neighborhood disparities in availability of prescription medications, Int. J. Health Geogr. 11 (2012) 48.
35. A. Bajpai, I. Savelieva, A.J. Camm, Treatment of atrial fibrillation, Br. Med. Bull. 88 (2008) 75-94.
36. G. Journath,M.L. Hellenius, A.C. Carlsson, P.E. Wandell, P.M. Nilsson, Physicians' gender is associated with risk factor control in patients on antihypertensive and lipid lowering treatment, Blood Press. 19 (2010) 240-248.
37. R. Bulbulia, L. Bowman, K. Wallendszus, S. Parish, J. Armitage, R. Peto, et al., Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: A randomised controlled trial, Lancet 378 (2011) 2013-2020.
38. G.Y. Lip, L. Frison, J.L. Halperin, D.A. Lane, Identifying patients at high risk for stroke despite anticoagulation: A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort, Stroke 41 (2010) 2731-2738.
39. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, H.J. Crijns, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation, Chest 137 (2010) 263-272.
40. K. Sundquist, A. Chaikiat, V.R. Leon, S.E. Johansson, J. Sundquist, Country of birth, socioeconomic factors, and risk factor control in patients with type 2 diabetes: A Swedish study from 25 primary health-care centres, Diabetes Metab. Res. Rev. 27 (2011) 244-254.